{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:42:54Z","timestamp":1784994174359,"version":"3.55.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n To assess whether the addition of rifampicin to conventional treatment of Staphylococcus aureus bacteraemia (SAB) reduces bacteriological or clinical failure or death.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, Embase and Cochrane CENTRAL databases were searched from inception to 31 December 2022. Reference lists and PubMed citations of eligible studies were checked.<\/jats:p>\n <\/jats:sec>\n \n Review methods<\/jats:title>\n Two study authors independently identified randomized controlled trials (RCTs) involving adult participants with SAB, in which an intervention group received adjunctive rifampicin and the control group received usual care with or without a placebo. Dichotomous data (bacteriological and clinical failure and deaths) were analysed and pooled across studies using risk ratio (RR) with 95% confidence intervals (CI) using a Mantel-Haenszel random-effect model. The key variable of interest being whether rifampicin was used.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Six RCTs including 894 participants\u2014of which 758 (85%) were from one trial\u2014met the inclusion criteria. The addition of rifampicin to conventional treatment of SAB significantly reduced bacteriological failure by 59% (RR 0.41, 95% CI 0.21\u20130.81, I2\u200a=\u200a0%, number need to treat 27). However, it did not reduce clinical failure (RR 0.70, 95% CI 0.47\u20131.03, I2\u200a=\u200a0%) or deaths (RR 0.96, 95% CI 0.70\u20131.32, I2\u200a=\u200a0%). Further, it did not reduce the duration of bacteraemia, or the length of hospital stay. Adjunctive rifampicin reduced SAB recurrences (1% versus 4%, P\u200a=\u200a0.01). Emergence of rifampicin resistance during treatment was uncommon (&lt;1%).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Although adjunctive rifampicin reduced the risk of bacteriological failure and recurrences, we found no mortality benefit to support its use in SAB.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/jac\/dkad214","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T04:10:14Z","timestamp":1692159014000},"page":"2419-2427","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of adjunctive rifampicin for treatment of Staphylococcus aureus<\/i> bacteraemia: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-6815","authenticated-orcid":false,"given":"R","family":"Dotel","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Blacktown Hospital , Sydney, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7490-6727","authenticated-orcid":false,"given":"G L","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Sydney Institute for Infectious Diseases, The University of Sydney , Sydney, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S N","family":"Hutabarat","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Liverpool Hospital , Liverpool, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J S","family":"Davis","sequence":"additional","affiliation":[{"name":"Menzies School of Health Research, Charles Darwin University , Darwin , Australia"},{"name":"John Hunter Hospital, University of Newcastle , Newcastle , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M V N","family":"O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"Sydney Institute for Infectious Diseases, The University of Sydney , Sydney, New South Wales , Australia"},{"name":"Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology\u2013Institute of Clinical Pathology and Medical Research, Westmead Hospital , Sydney, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"2023100302094613400_dkad214-B1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2023100302094613400_dkad214-B2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023100302094613400_dkad214-B3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/cid\/civ120","article-title":"Impact of infectious disease consultation on quality of care, mortality, and length of stay in Staphylococcus aureus bacteremia: results from a large multicenter cohort study","volume":"60","author":"Bai","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023100302094613400_dkad214-B4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"key":"2023100302094613400_dkad214-B5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/CMR.00034-09","article-title":"Rifampin combination therapy for nonmycobacterial infections","volume":"23","author":"Forrest","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2023100302094613400_dkad214-B6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrmicro2508","article-title":"Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus?","volume":"9","author":"Thwaites","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"2023100302094613400_dkad214-B7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1099\/jmm.0.072280-0","article-title":"Adjunctive rifampicin may improve outcomes in Staphylococcus aureus bacteraemia: a systematic review","volume":"63","author":"Russell","year":"2014","journal-title":"J Med Microbiol"},{"key":"2023100302094613400_dkad214-B8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/archinte.168.8.805","article-title":"Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature","volume":"168","author":"Perlroth","year":"2008","journal-title":"Arch Intern Med"},{"key":"2023100302094613400_dkad214-B9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) study group","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"2023100302094613400_dkad214-B10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1745-6215-13-241","article-title":"Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial","volume":"13","author":"Thwaites","year":"2012","journal-title":"Trials"},{"key":"2023100302094613400_dkad214-B11","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/microorganisms10050848","article-title":"The effectiveness of combination therapy for treating methicillin-susceptible Staphylococcus aureus bacteremia: a systematic literature review and a meta-analysis","volume":"10","author":"Grillo","year":"2022","journal-title":"Microorganisms"},{"key":"2023100302094613400_dkad214-B12","doi-asserted-by":"crossref","first-page":"e0230383","DOI":"10.1371\/journal.pone.0230383","article-title":"Adjunctive rifampin for the treatment of Staphylococcus aureus bacteremia with deep infections: a meta-analysis","volume":"15","author":"Ma","year":"2020","journal-title":"PLoS ONE"},{"key":"2023100302094613400_dkad214-B13","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023100302094613400_dkad214-B14","author":"Higgins","year":"2022"},{"key":"2023100302094613400_dkad214-B15","author":"Anon","year":"2022"},{"key":"2023100302094613400_dkad214-B16","doi-asserted-by":"crossref","first-page":"e073141","DOI":"10.1136\/bmj-2022-073141","article-title":"Methods for deriving risk difference (absolute risk reduction) from a meta-analysis","volume":"381","author":"Murad","year":"2023","journal-title":"BMJ"},{"key":"2023100302094613400_dkad214-B17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CCM.0b013e3181b9ecea","article-title":"Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia","volume":"38","author":"Jung","year":"2010","journal-title":"Crit Care Med"},{"key":"2023100302094613400_dkad214-B18","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1128\/AAC.00096-06","article-title":"Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia","volume":"50","author":"Weems","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302094613400_dkad214-B19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2796.2005.01598.x","article-title":"Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients","volume":"259","author":"Ruotsalainen","year":"2006","journal-title":"J Intern Med"},{"key":"2023100302094613400_dkad214-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22590","article-title":"Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT","volume":"22","author":"Thwaites","year":"2018","journal-title":"Health Technol Assess"},{"key":"2023100302094613400_dkad214-B21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1128\/AAC.28.4.467","article-title":"Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections","volume":"28","author":"Van der Auwera","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"2023100302094613400_dkad214-B22","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.1093\/clinids\/5.Supplement_3.S515","article-title":"Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections","volume":"5","author":"Van der Auwera","year":"1983","journal-title":"Rev Infect Dis"},{"key":"2023100302094613400_dkad214-B23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis","volume":"115","author":"Levine","year":"1991","journal-title":"Ann Intern Med"},{"key":"2023100302094613400_dkad214-B24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9343(96)00070-8","article-title":"Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy","volume":"101","author":"Heldman","year":"1996","journal-title":"Am J Med"},{"key":"2023100302094613400_dkad214-B25","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/424506","article-title":"A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection","volume":"39","author":"Schrenzel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2023100302094613400_dkad214-B26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jinf.2019.08.001","article-title":"Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: observational analyses within the ARREST trial","volume":"79","author":"Szubert","year":"2019","journal-title":"J Infect"},{"key":"2023100302094613400_dkad214-B27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"2023100302094613400_dkad214-B28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2023100302094613400_dkad214-B29","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1093\/cid\/ciaa1000","article-title":"Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a randomized, controlled trial","volume":"72","author":"Cheng","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023100302094613400_dkad214-B30","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/cid\/ciaa1081","article-title":"Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial","volume":"72","author":"Pujol","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023100302094613400_dkad214-B31","doi-asserted-by":"crossref","first-page":"dlac014","DOI":"10.1093\/jacamr\/dlac014","article-title":"Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE)-an open-labelled pilot randomized controlled trial","volume":"4","author":"Campbell","year":"2022","journal-title":"JAC-antimicrobial Resist"},{"key":"2023100302094613400_dkad214-B32","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciac476","article-title":"The Staphylococcus aureus network adaptive platform trial protocol: new tools for an old foe","volume":"75","author":"Tong","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023100302094613400_dkad214-B33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/dkl044","article-title":"The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials","volume":"57","author":"Falagas","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2023100302094613400_dkad214-B34","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1473-3099(10)70285-1","article-title":"Clinical management of Staphylococcus aureus bacteraemia","volume":"11","author":"Thwaites","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2023100302094613400_dkad214-B35","doi-asserted-by":"crossref","first-page":"ofac583","DOI":"10.1093\/ofid\/ofac583","article-title":"Deconstructing the Dogma: systematic literature review and meta-analysis of adjunctive gentamicin and rifampin in staphylococcal prosthetic valve endocarditis","volume":"9","author":"Ryder","year":"2022","journal-title":"Open forum Infect Dis"},{"key":"2023100302094613400_dkad214-B36","doi-asserted-by":"crossref","first-page":"e033540","DOI":"10.1136\/bmjopen-2019-033540","article-title":"Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): a protocol for two open-label randomized controlled trials","volume":"10","author":"Lemaignen","year":"2020","journal-title":"BMJ Open"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/10\/2419\/51743474\/dkad214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/10\/2419\/51743474\/dkad214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:10:53Z","timestamp":1696299053000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/10\/2419\/7242635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,8,16]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad214","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,8,16]]}}}